- Organizations: Aurion Biotech
Pipeline
Aurion Biotech begins dosing in phase 3 trial on allogeneic cell therapy for CED
The ASTRA study kicks off evaluating AURN001, designed to regenerate corneal clarity and vision through an intracameral injection.
Business
Leadership watch: KALA BIO names new CEO, Aurion Biotech promotes execs
Aurion makes its move ahead of initiating a phase 3 trial in early 2026 for its allogeneic cell therapy, under evaluation for corneal endothelial disease.
Business
Alcon purchases majority stake in Aurion Biotech
Company replaces CEO and founder Greg Kunst, gaining access to groundbreaking CED cell therapy with plans for phase 3 clinical trials expected later this year.Pipeline
Aurion Biotech releases topline phase 1/2 data on allogeneic cell therapy for CED
Findings support potential for high-dose AURN001 as a one-time intracameral injection that regenerates healthy cells from a single donor cornea.
Events
KOLs eye the future of genetic engineering and cell transplantation
Industry leaders from four leading ophthalmic companies debut the latest clinical developments in cell-based therapeutics.
Pipeline
FDA grants Breakthrough Therapy Designation, RMAT to Aurion's CED cell therapy
AURN001 is now the first allogeneic cell therapy to be granted two designations for corneal edema secondary to CED.
Pipeline